₩1,398,000.00
0.14%
Korea, Sep 18, 03:30 pm KST. Closed.
ISIN
KR7207940008
Symbol
207940
Index

SAMSUNG BIOLOGICS Target price 2026 - Analyst rating & recommendation

SAMSUNG BIOLOGICS Classifications & Recommendation

Buy
97%
Hold
3%

SAMSUNG BIOLOGICS Price Target

Target Price ₩2,065,500.00
Price ₩1,398,000.00
Potential
Number of Estimates 30
30 Analysts have issued a price target SAMSUNG BIOLOGICS 2027 . The average SAMSUNG BIOLOGICS target price is ₩2,065,500.00. This is higher than the current stock price. The highest price target is
₩2,421,620.00 73.22%
register free of charge
, the lowest is
₩1,616,000.00 15.59%
register free of charge
.
A rating was issued by 33 analysts: 32 Analysts recommend SAMSUNG BIOLOGICS to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the SAMSUNG BIOLOGICS stock has an average upside potential 2027 of . Most analysts recommend the SAMSUNG BIOLOGICS stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Billion ₩ 4,556.97 5,499.43
0.21% 20.68%
EBITDA Margin 46.11% 52.41%
53.47% 13.66%
Net Margin 39.16% 33.78%
64.36% 13.73%

27 Analysts have issued a sales forecast SAMSUNG BIOLOGICS 2026 . The average SAMSUNG BIOLOGICS sales estimate is

₩5.5t
unlock
. This is
20.95% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
₩5.9t 30.60%
unlock
, the lowest is
₩5.0t 10.89%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 ₩4.6t 0.21%
2026
₩5.5t 20.68%
unlock
2027
₩6.4t 16.57%
unlock
2028
₩7.1t 10.56%
unlock
2029
₩8.1t 14.54%
unlock
2030
₩9.2t 13.68%
unlock
2031
₩9.5t 3.28%
unlock
2032
₩11.1t 16.55%
unlock

28 Analysts have issued an SAMSUNG BIOLOGICS EBITDA forecast 2026. The average SAMSUNG BIOLOGICS EBITDA estimate is

₩2.9t
unlock
. This is
24.98% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
₩3.2t 39.40%
unlock
, the lowest is
₩2.5t 9.73%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 ₩2.1t 53.80%
2026
₩2.9t 37.16%
unlock
2027
₩3.3t 15.84%
unlock
2028
₩3.7t 11.99%
unlock
2029
₩5.1t 37.32%
unlock
2030
₩5.9t 15.20%
unlock

EBITDA Margin

2025 46.11% 53.47%
2026
52.41% 13.66%
unlock
2027
52.08% 0.63%
unlock
2028
52.75% 1.29%
unlock
2029
63.25% 19.91%
unlock
2030
64.09% 1.33%
unlock

29 SAMSUNG BIOLOGICS Analysts have issued a net profit forecast 2026. The average SAMSUNG BIOLOGICS net profit estimate is

₩1.9t
unlock
. This is
6.37% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
₩2.2t 9.86%
unlock
, the lowest is
₩1.0t 48.72%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 ₩1.8t 64.71%
2026
₩1.9t 4.13%
unlock
2027
₩2.2t 18.99%
unlock
2028
₩2.5t 12.37%
unlock

Net Margin

2025 39.16% 64.36%
2026
33.78% 13.73%
unlock
2027
34.49% 2.10%
unlock
2028
35.05% 1.62%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share 40,941.60 40,181.19
74.95% 1.86%
P/E 34.79
EV/Sales 11.58

29 Analysts have issued a SAMSUNG BIOLOGICS forecast for earnings per share. The average SAMSUNG BIOLOGICS EPS is

₩40,181.19
unlock
. This is
6.37% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
₩47,143.10 9.86%
unlock
, the lowest is
₩22,006.76 48.72%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 ₩40,941.60 74.95%
2026
₩40,181.19 1.86%
unlock
2027
₩47,810.46 18.99%
unlock
2028
₩53,726.42 12.37%
unlock

P/E ratio

Current 32.58 41.14%
2026
34.79 6.79%
unlock
2027
29.24 15.95%
unlock
2028
26.02 11.01%
unlock

Based on analysts' sales estimates for 2026, the SAMSUNG BIOLOGICS stock is valued at an EV/Sales of

11.58
unlock
and an P/S ratio of
11.75
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 14.00 4.18%
2026
11.58 17.30%
unlock
2027
9.93 14.22%
unlock
2028
8.98 9.55%
unlock
2029
7.84 12.69%
unlock
2030
6.90 12.03%
unlock
2031
6.68 3.18%
unlock
2032
5.73 14.20%
unlock

P/S ratio

Current 14.21 3.01%
2026
11.75 17.32%
unlock
2027
10.08 14.22%
unlock
2028
9.12 9.55%
unlock
2029
7.96 12.69%
unlock
2030
7.00 12.03%
unlock
2031
6.78 3.18%
unlock
2032
5.82 14.20%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today